84 related articles for article (PubMed ID: 19357545)
1. Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance.
Urushihara H; Kikuchi N; Yamada M; Yoshiki F; Miyauchi A
Menopause; 2009; 16(5):971-7. PubMed ID: 19357545
[TBL] [Abstract][Full Text] [Related]
2. Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis: a prospective, postmarketing observational study.
Yoh K; Hamaya E; Urushihara H; Iikuni N; Yamamoto T; Taketsuna M; Miyauchi A; Sowa H; Tanaka K
Curr Med Res Opin; 2012 Nov; 28(11):1757-66. PubMed ID: 23035693
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene and risk for stroke based on the framingham stroke risk score.
Barrett-Connor E; Cox DA; Song J; Mitlak B; Mosca L; Grady D
Am J Med; 2009 Aug; 122(8):754-61. PubMed ID: 19540454
[TBL] [Abstract][Full Text] [Related]
4. Safety of 3-year raloxifene treatment in Japanese postmenopausal women aged 75 years or older with osteoporosis: a postmarketing surveillance study.
Takeuchi Y; Hamaya E; Taketsuna M; Sowa H
Menopause; 2015 Oct; 22(10):1134-7. PubMed ID: 25756692
[TBL] [Abstract][Full Text] [Related]
5. Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
Barrett-Connor E; Cauley JA; Kulkarni PM; Sashegyi A; Cox DA; Geiger MJ
J Bone Miner Res; 2004 Aug; 19(8):1270-5. PubMed ID: 15231013
[TBL] [Abstract][Full Text] [Related]
6. Safety assessment of raloxifene over eight years in a clinical trial setting.
Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
[TBL] [Abstract][Full Text] [Related]
7. Is diabetes mellitus a heart disease equivalent in women? Results from an international study of postmenopausal women in the Raloxifene Use for the Heart (RUTH) Trial.
Daniels LB; Grady D; Mosca L; Collins P; Mitlak BH; Amewou-Atisso MG; Wenger NK; Barrett-Connor E;
Circ Cardiovasc Qual Outcomes; 2013 Mar; 6(2):164-70. PubMed ID: 23481531
[TBL] [Abstract][Full Text] [Related]
8. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
9. Re: Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance.
Hamaya E; Sowa H
Menopause; 2014 Jan; 21(1):109-10. PubMed ID: 24281238
[No Abstract] [Full Text] [Related]
10. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
Lu PY; Hsieh CF; Tsai YW; Huang WF
Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
[TBL] [Abstract][Full Text] [Related]
11. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis.
Ensrud K; Genazzani AR; Geiger MJ; McNabb M; Dowsett SA; Cox DA; Barrett-Connor E
Am J Cardiol; 2006 Feb; 97(4):520-7. PubMed ID: 16461049
[TBL] [Abstract][Full Text] [Related]
12. Quality of life in Japanese women with postmenopausal osteoporosis treated with raloxifene and vitamin D: post hoc analysis of a postmarketing study.
Ohta H; Hamaya E; Taketsuna M; Sowa H
Curr Med Res Opin; 2015 Jan; 31(1):85-94. PubMed ID: 25299349
[TBL] [Abstract][Full Text] [Related]
13. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis.
Adomaityte J; Farooq M; Qayyum R
Thromb Haemost; 2008 Feb; 99(2):338-42. PubMed ID: 18278183
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
[TBL] [Abstract][Full Text] [Related]
15. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease.
Mosca L; Grady D; Barrett-Connor E; Collins P; Wenger N; Abramson BL; Paganini-Hill A; Geiger MJ; Dowsett SA; Amewou-Atisso M; Kornitzer M
Stroke; 2009 Jan; 40(1):147-55. PubMed ID: 18948611
[TBL] [Abstract][Full Text] [Related]
16. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
17. Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.
Bachmann G; Crosby U; Feldman RA; Ronkin S; Constantine GD
Menopause; 2011 May; 18(5):508-14. PubMed ID: 21289525
[TBL] [Abstract][Full Text] [Related]
18. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
[TBL] [Abstract][Full Text] [Related]
19. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
20. Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration.
Scharla S; Oertel H; Helsberg K; Kessler F; Langer F; Nickelsen T
Curr Med Res Opin; 2006 Dec; 22(12):2393-402. PubMed ID: 17257453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
